Maddalena Adorno et al. showed that TGF-β-dependent tumour progression is promoted in the presence of mutant p53, which can intercept p63 (an antagonist of TGF-β) to drive the TGF-β-mediated promotion of tumour invasiveness and metastasis 43. The gene discussed is TP53; the disease is neoplasm.